Navigation Links
Biotech Shows Glimmer of an Upward Trend
Date:6/1/2009

SAN FRANCISCO, June 1 /PRNewswire/ -- The markets closed out May in positive territory following on from their April performance...which was their best month in nine years. The Dow Jones industrial average posted its third straight monthly gain closing up 4 percent with the Nasdaq close behind - up 3.3 percent in May. The positive market trend helped biotech with the Burrill Biotech Select Index posting a modest monthly gain of 0.4 percent.

"There is just a glimmer of an upward trend for biotech as evidenced by the performance of the Burrill Mid-Cap Biotech Index, whose members have been particularly hard hit during this economic downturn," said G. Steven Burrill, CEO, Burrill & Company, a San Francisco based global leader in life sciences with activities in Private Equity, Venture Capital, Merchant Banking and Media. "For the past couple of months some of the companies in the Index, such as Cougar Biotech, Geron, and Dendreon, have been on a tear pushing the year-to-date performance of the Index up a remarkable 16 percent, with a 5 percent jump in May alone.

Vaulting development stage biopharmaceutical company Cougar Biotechnology's share value by 33 percent in May was the news that Johnson & Johnson bid approximately $970 million cash to acquire the company and gain access to compounds in development for the treatment of prostate cancer, as well as breast cancer and multiple myeloma. Cougar Biotechnology is currently conducting two Phase III trials for abiraterone acetate, a late stage, first-in-class compound for the treatment of prostate cancer.

"The predicted land grab of biotech by big pharma because of their depressed values has not yet panned out with pharma companies preferring to acquire each other. However, we may now see an upswing in M&A activity heading into the summer months, since the Johnson & Johnson acquisition of Cougar may prompt pharma, who have been generally sitting on the sidelines, to 'pull the trigger' on biotech deals so that they don't lose out to their competitors," added Burrill.

Shares of Dendreon have increased in value by a whopping 440 percent since the company first announced it had positive Phase III data that showed its lead product Provenge extended the lives of men with advanced prostate cancer by an average of 4.1 months. According to analysts, Dendreon should be able to file for regulatory approval during the fourth quarter 2009. On the basis of its positive clinical data and strengthening share price the company raised $221 million, the second best biotech financing deal so far this year, to help fund the manufacture and sale of Provenge.

"While the industry overall is still going through tough times, and we predict it is still going to take many more months before biotech starts on the road to full recovery it is encouraging to see that investors are prepared to reward biotech companies that do achieve significant milestones," Burrill noted.

"In addition, despite the prevailing economic recession and travel restrictions some countries imposed because of the H1N1 flu outbreak, the 2009 BIO International Convention, held this month, attracted well over 14,000 attendees to Atlanta, Georgia," added Burrill. "The success of the meeting demonstrates that business is still ongoing and companies are actively looking for strategies and partners to help them get through the challenges that they are currently facing."

By the Numbers

The monthly Burrill Report (www.burrillreport.com) provides ongoing statistics and analysis on the 343 biotechs that are publicly traded on major US markets. Among the current data the publication reports that: at the end of May this group of companies had an aggregate market cap of $297.6 billion (up 3.6 percent for the month). Also:

    - There are 43 companies that have market caps greater than $1B
    - 154 public biotech companies (44%) have a market cap below $100 million
    - 69 are trading below their cash level
    - Over 110 companies have announced a corporate restructuring by slashing
    staff and putting promising projects in the refrigerator
    - YTD the Burrill Biotech Select Index has fallen 7 percent
    - The performance of the top five biotech companies since the beginning of
    the year:
    Amgen (-13.8 percent); Gilead Sciences (-16.5 percent); Celgene (-24
    percent); Genzyme (-11 percent); and Biogen (+ 8.6 percent).


'/>"/>
SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in an ... on RFD-TV. , With global population estimates nearing ten billion people by 2050, ... a growing nation. At the same time, many of our valuable resources are becoming ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):